Free Trial

Burning Rock Biotech (BNR) Competitors

$6.26
0.00 (0.00%)
(As of 07/12/2024 ET)

BNR vs. GTH, BDSX, SERA, PSNL, ENZ, XGN, RNLX, PMD, BGLC, and OPGN

Should you be buying Burning Rock Biotech stock or one of its competitors? The main competitors of Burning Rock Biotech include Genetron (GTH), Biodesix (BDSX), Sera Prognostics (SERA), Personalis (PSNL), Enzo Biochem (ENZ), Exagen (XGN), Renalytix (RNLX), Psychemedics (PMD), BioNexus Gene Lab (BGLC), and OpGen (OPGN).

Burning Rock Biotech vs.

Genetron (NASDAQ:GTH) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.

10.7% of Genetron shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genetron
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Burning Rock Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Genetron has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

In the previous week, Burning Rock Biotech had 3 more articles in the media than Genetron. MarketBeat recorded 3 mentions for Burning Rock Biotech and 0 mentions for Genetron. Genetron's average media sentiment score of 1.25 beat Burning Rock Biotech's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Genetron Neutral
Burning Rock Biotech Positive

Burning Rock Biotech received 3 more outperform votes than Genetron when rated by MarketBeat users. However, 33.33% of users gave Genetron an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.

CompanyUnderperformOutperform
GenetronOutperform Votes
2
33.33%
Underperform Votes
4
66.67%
Burning Rock BiotechOutperform Votes
5
31.25%
Underperform Votes
11
68.75%

Burning Rock Biotech has lower revenue, but higher earnings than Genetron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$94.34M1.35-$117.21MN/AN/A
Burning Rock Biotech$75.70M0.85-$92.07M-$6.46-0.97

Genetron has a net margin of 0.00% compared to Genetron's net margin of -113.39%. Burning Rock Biotech's return on equity of 0.00% beat Genetron's return on equity.

Company Net Margins Return on Equity Return on Assets
GenetronN/A N/A N/A
Burning Rock Biotech -113.39%-71.22%-52.22%

Summary

Genetron beats Burning Rock Biotech on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNR vs. The Competition

MetricBurning Rock BiotechMedical laboratories IndustryBusiness SectorNASDAQ Exchange
Market Cap$64.10M$2.27B$7.01B$8.70B
Dividend YieldN/A1.99%2.50%4.05%
P/E Ratio-0.9715.4918.8716.16
Price / Sales0.85129.361,144.6479.14
Price / CashN/A327.2525.6032.70
Price / Book0.594.184.444.46
Net Income-$92.07M-$128.23M$122.13M$215.59M
7 Day Performance2.62%7.21%2.82%5.35%
1 Month Performance-18.81%2.99%1.39%3.36%
1 Year Performance-71.55%-11.77%-0.64%0.94%

Burning Rock Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GTH
Genetron
0 of 5 stars
0.00 / 5 stars
$4.03
+0.2%
N/A+46.0%$127.43M$94.34M0.00993High Trading Volume
BDSX
Biodesix
2.5269 of 5 stars
2.53 / 5 stars
$1.59
+1.3%
$3.10
+95.0%
+43.8%$182.36M$49.09M-2.89217Short Interest ↑
News Coverage
SERA
Sera Prognostics
0.6336 of 5 stars
0.63 / 5 stars
$5.38
-0.2%
$2.75
-48.9%
+93.9%$175.66M$310,000.00-5.0355
PSNL
Personalis
4.3655 of 5 stars
4.37 / 5 stars
$1.51
-1.3%
$5.00
+231.1%
-27.8%$78.43M$73.48M-0.79223Gap Up
High Trading Volume
ENZ
Enzo Biochem
0 of 5 stars
0.00 / 5 stars
$1.04
-1.9%
N/A-23.2%$53.52M$33.34M0.00179Short Interest ↑
Positive News
Gap Down
XGN
Exagen
4.6465 of 5 stars
4.65 / 5 stars
$1.78
+1.7%
$7.00
+294.4%
-31.6%$30.83M$52.55M-1.63174Short Interest ↑
News Coverage
RNLX
Renalytix
1.9627 of 5 stars
1.96 / 5 stars
$0.27
+7.9%
N/A-91.3%$21.10M$3.40M-0.70102Analyst Forecast
Short Interest ↑
News Coverage
Gap Down
PMD
Psychemedics
0 of 5 stars
0.00 / 5 stars
$2.40
-1.2%
N/A-43.6%$13.94M$22.10M-3.12116Short Interest ↑
BGLC
BioNexus Gene Lab
0 of 5 stars
0.00 / 5 stars
$0.48
+4.4%
N/AN/A$8.46M$9.77M0.0030Short Interest ↑
Gap Up
OPGN
OpGen
0 of 5 stars
0.00 / 5 stars
$2.75
+3.0%
N/A-64.4%$3.69M$3.42M-0.0485Analyst Forecast
News Coverage

Related Companies and Tools

This page (NASDAQ:BNR) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners